Flow Cytometric Evaluation of Biomarkers

临床定量流式细胞术是一项利用专门的抗体染色技术和荧光标准来定量抗体与样品中不同细胞群结合的新技术。流式细胞术单位使用这种技术定量肿瘤细胞抗体结合能力的病人接受各种抗体为基础的治疗。流式细胞术检测代替了以前使用放射性标记抗体的研究。流式细胞术检测更快速，不需要使用放射性，并且在100 uL的血液中进行，而不是25mL。收集的数据也更精确，提高了NCI研究人员比较抗体与肿瘤细胞结合和治疗反应的能力。治疗后立即定量荧光抗体结合也可以精确测定抗原位点的饱和度与非标记的治疗性抗体。由于大多数NCI淋巴瘤和白血病方案在其方案中包括基于抗体的治疗，这对NCI研究者来说是一个巨大的资源。参考实验室不提供抗体结合定量。

Clinical quantitative flow cytometry is a new technology that utilizes specialized antibody staining techniques and fluorescent standards to quantitate antibody binding to different cell populations within a sample. The Flow Cytometry Unit uses this technique to quantitate tumor cell antibody binding capacity in patients undergoing various antibody based therapies. The flow cytometric assays are performed in place of previous studies using radioactively labeled antibodies. The flow cytometric assays are more rapid, make the use of radioactivity unnecessary and are performed on 100 uL of blood instead of 25mL. The data collected is also more precise and improves the ability of NCI investigators to compare antibody binding to tumor cells to treatment response. Quantitation of fluorescent antibody binding immediately post therapy also allows precise determination of saturation of antigen sites with non labeled therapeutic antibody. As the majority of NCI lymphoma and leukemia protocols include antibody based therapy in their regimens, this is a tremendous resource for NCI investigators. Antibody binding quantitation is not provided by reference laboratories.